Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 2:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 539 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Vaccine 3 Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Administered With a Yellow Fever Vaccine in Adults

NCT03342898
View directory record Official record
Conditions
Dengue
Interventions
YF-17D, TDV, Placebo
Biological · Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 60 Years
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
11
States / cities
Mobile, Alabama • Pomona, California • Meridian, Idaho + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 18, 2026, 2:03 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Sudan Ebolavirus Vaccine in Healthy Adults

NCT06803342
View directory record Official record
Conditions
Ebola Sudan Virus Disease
Interventions
cAd3-Sudan Vaccine, Placebo
Biological
Lead sponsor
Albert B. Sabin Vaccine Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
4
States / cities
Phoenix, Arizona • Melbourne, Florida • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 18, 2026, 2:03 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Post Marking Study to Evaluate the Safety of FluMist in Children

NCT00569894
View directory record Official record
Conditions
Healthy
Interventions
FLuMist, TIV (Injection), Unvaccinated Control
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
24 Months to 59 Months
Enrollment
29,296 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Mar 8, 2012 · Synced Oct 18, 2026, 2:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Norwalk Vaccine Study

NCT00806962
View directory record Official record
Conditions
Norovirus
Interventions
Adjuvant/Excipients, placebo, Norwalk VLP Vaccine
Drug · Device · Biological
Lead sponsor
LigoCyte Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
4
States / cities
Baltimore, Maryland • St Louis, Missouri • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 6, 2015 · Synced Oct 18, 2026, 2:03 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants

NCT04228783
View directory record Official record
Conditions
Ebola
Interventions
Ad26.ZEBOV, MVA-BN-Filo, Placebo
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 50 Years
Enrollment
974 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
7
States / cities
Mobile, Alabama • Tempe, Arizona • Lexington, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 18, 2026, 2:03 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Safety, Tolerability, & Immunogenicity of Multiple Formulations of BNT162b2 Against COVID-19 in Healthy Adults

NCT04816669
View directory record Official record
Conditions
SARS-CoV-2 Infection, COVID-19
Interventions
BNT162b2
Biological
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years to 55 Years
Enrollment
629 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
21
States / cities
Anaheim, California • Walnut Creek, California • Hialeah, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2022 · Synced Oct 18, 2026, 2:03 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Detoxified J5 Core Glycolipid/ Group B Meningococcal Outer Membrane Protein Vaccine for Gram-negative Bacterial Sepsis Administered With and Without Synthetic CPG Oligodeoxynucleotide 7909 Adjuvant

NCT01164514
View directory record Official record
Conditions
Bacterial Sepsis
Interventions
CPG 7909, J5-OMP Vaccine, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 31, 2014 · Synced Oct 18, 2026, 2:03 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer

NCT05141721
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
GRT-C901, GRT-R902, Atezolizumab, Ipilimumab, Fluoropyrimidine plus leucovorin, Bevacizumab
Drug
Lead sponsor
Seattle Project Corporation
Industry
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
43
States / cities
Gilbert, Arizona • Springdale, Arkansas • Los Angeles, California + 36 more
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 18, 2026, 2:03 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Efficacy of Na-GST-1/Alhydrogel Hookworm Vaccine Assessed by Controlled Challenge Infection

NCT03172975
View directory record Official record
Conditions
Hookworm Infections
Interventions
Na-GST-1/Alhydrogel, Na-GST-1/Alhydrogel + CPG 10104, Na-GST-1/Alhydrogel + GLA-AF, Placebo, Albendazole, Necator americanus Larval Inoculum
Biological · Drug · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 45 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 18, 2026, 2:03 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine

NCT00289783
View directory record Official record
Conditions
Haemophilus Influenzae Type b, Neisseria Meningitidis
Interventions
GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis 792014 vaccine, ActHIB, PedvaxHIB, Pediarix, Prevnar, M-M-R II, Varivax
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 15 Months
Enrollment
4,441 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
88
States / cities
Birmingham, Alabama • Phoenix, Arizona • Bryant, Arkansas + 76 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2018 · Synced Oct 18, 2026, 2:03 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Multisite Observational Maternal and Infant Study for COVID-19

NCT05031468
View directory record Official record
Conditions
COVID-19
Interventions
Licensed or EUA SARS-CoV-2 vaccine
Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
562 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
10
States / cities
Atlanta, Georgia • Chicago, Illinois • New York, New York + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2024 · Synced Oct 18, 2026, 2:03 AM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Induction of Gut Permeability by an Oral Vaccine

NCT04083950
View directory record Official record
Conditions
Intestinal Permeability, Inflammation, Vaccine, Typhoid Fever
Interventions
Vivotif Typhoid Oral Vaccine, Aspirin (Positive Control)
Biological · Drug
Lead sponsor
USDA, Western Human Nutrition Research Center
Federal
Eligibility
18 Years to 49 Years · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Oct 18, 2026, 2:03 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young Adults

NCT04502693
View directory record Official record
Conditions
Infections, Meningococcal
Interventions
rMenB+OMV NZ vaccine, Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY), Placebo, MenABCWY-1, MenABCWY-2, MenABCWY-3
Combination Product · Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
10 Years to 25 Years
Enrollment
3,657 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
64
States / cities
Chandler, Arizona • Glendale, Arizona • Jonesboro, Arkansas + 51 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Oct 18, 2026, 2:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bivalent Norovirus Vaccine Study

NCT01168401
View directory record Official record
Conditions
Gastroenteritis
Interventions
NoV GI.1/GII.4 Bivalent VLP Vaccine, Saline
Biological
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 85 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
3
States / cities
Silver Springs, Maryland • St Louis, Missouri • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 23, 2018 · Synced Oct 18, 2026, 2:03 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age

NCT05975099
View directory record Official record
Conditions
Lyme Disease
Interventions
mRNA-1975, mRNA-1982, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
807 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
20
States / cities
Milford, Connecticut • Stamford, Connecticut • Waterbury, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 18, 2026, 2:03 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Phase I Dose Escalation SARS-CoV Recombinant S Protein, With and Without Adjuvant, Vaccine Study

NCT01376765
View directory record Official record
Conditions
SARS
Interventions
Aluminum hydroxide adjuvant (Alhydrogel®), Phosphate buffered saline Placebo, Recombinant S protein SARS vaccine
Drug · Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Healthy volunteers
Accepts healthy volunteers
U.S. locations
3
States / cities
Iowa City, Iowa • St Louis, Missouri • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 15, 2013 · Synced Oct 18, 2026, 2:03 AM EDT
Completed Phase 2 Interventional

A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3

NCT01304524
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia
Interventions
VGX 3100, Placebo, CELLECTRA™-5P
Biological · Device
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
27
States / cities
Phoenix, Arizona • Tucson, Arizona • Colton, California + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2018 · Synced Oct 18, 2026, 2:03 AM EDT
Terminated Phase 3 Interventional Results available

A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702)

NCT03520959
View directory record Official record
Conditions
Synovial Sarcoma, Cancer, Soft Tissue Sarcoma, Sarcoma, Metastatic Sarcoma
Interventions
LV305, G305, LV305-matching placebo, G305-matching placebo
Biological · Other
Lead sponsor
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
12 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
27
States / cities
Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2020 · Synced Oct 18, 2026, 2:03 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of ChimeriVax-WN02 West Nile Vaccine in Healthy Adults

NCT00442169
View directory record Official record
Conditions
West Nile Fever
Interventions
ChimeriVax-WN02 Low Dose, ChimeriVax-WN02 Medium Dose, ChimeriVax-WN02 High Dose, 0.9% Saline solution, 0.9 % NaCl solution
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
5
States / cities
Phoenix, Arizona • Idaho Falls, Idaho • Lenexa, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 18, 2026, 2:03 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate a Range of Dose Levels of an Adenovirus Serotype 26 (Ad26.RSV.preF)-Based Vaccine in Older Adults

NCT04453202
View directory record Official record
Conditions
Healthy
Interventions
RSV Vaccine, Placebo
Biological · Other
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
60 Years and older
Enrollment
459 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
9
States / cities
San Diego, California • Coral Gables, Florida • El Dorado, Kansas + 6 more
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 18, 2026, 2:03 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

NCT06736041
View directory record Official record
Conditions
Pneumococcal Immunization
Interventions
PCV21 vaccine, Prevnar 20 vaccine, M-M-R II vaccine, RotaTeq, Vaxelis vaccine, Varivax, Hexaxim Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
42 Days to 89 Days
Enrollment
1,714 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
66
States / cities
Glendale, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 48 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 18, 2026, 2:03 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Phase 1/2, Randomized, Placebo-controlled, Observer-blinded Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A Multivalent Group B Streptococcus Vaccine In Healthy Adults 18 To 49 Years Of Age

NCT03170609
View directory record Official record
Conditions
Group B Streptococcal Infections
Interventions
Multivalent group B streptococcus vaccine, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 49 Years
Enrollment
365 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
4
States / cities
Stockbridge, Georgia • Bardstown, Kentucky • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 2, 2019 · Synced Oct 18, 2026, 2:03 AM EDT
Completed Not applicable Interventional Results available

Safe Administration of Flu Vaccine to Egg Allergic Children

NCT01264601
View directory record Official record
Conditions
Egg Allergy
Interventions
Trivalent Influenza Vaccine
Biological
Lead sponsor
University of Michigan
Other
Eligibility
6 Months to 24 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
5
States / cities
San Diego, California • Ann Arbor, Michigan • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2017 · Synced Oct 18, 2026, 2:03 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Live Attenuated ETEC Vaccine ACE527 With and Without dmLT Adjuvant in Adults

NCT01739231
View directory record Official record
Conditions
Diarrhea
Interventions
ACE527, dmLT, CeraVacx placebo, H10407 challenge strain
Biological
Lead sponsor
PATH
Other
Eligibility
18 Years to 50 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 12, 2019 · Synced Oct 18, 2026, 2:03 AM EDT